Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.TCRT · Entity 8339 | Director · See Remarks | March 29, 2025 | April 01, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date March 29, 2025 · Filed April 01, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.46 · Expires 2035-03-28 | Direct | 3,000 |
Reported balance
After 2025-03-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-29 · Grant · Acquired 3,000 · Balance 3,000 F1: One-sixth of the shares underlying the option vest in equal monthly installments measured from March 29, 2025, with the first vesting occurring on April 29, 2025 subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-sixth of the shares underlying the option vest in equal monthly installments measured from March 29, 2025, with the first vesting occurring on April 29, 2025 subject to the Reporting Person's continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 29, 2025 Filed Apr 1, 2025 20:21 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0000950170-25-048554 · ownership.xml · derivative · entry 1 Hogue Dale Curtis Jr. · CIK 0002006649 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2035-03-28 F1 · derivative.exercise_date: One-sixth of the shares underlying the option vest in equal monthly installments measured from March 29, 2025, with the first vesting occurring on April 29, 2025 subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| January 20, 2024 Filed Jan 23, 2024 22:47 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0000950170-24-006700 · ownership.xml · derivative · entry 1 Hogue Dale Curtis Jr. · CIK 0002006649 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2034-01-19 F1 · derivative.exercise_date: In twelve equal monthly installments measured from January 20, 2024, with the first vesting occurring on February 20, 2024, subject to the Reporting Person's continued service through each such date. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 22:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 41,667 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0000950170-24-001195 · ownership.xml · derivative · entry 2 Hogue Dale Curtis Jr. · CIK 0002006649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,667 Underlying: Common Stock · 41,667 shares Expires 2033-12-28 F2 · derivative.exercise_date: In five equal monthly installments measured from December 29, 2023, with the first vesting occurring on January 29, 2024, subject to the Reporting Person's continued service through each such date. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 22:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0000950170-24-001195 · ownership.xml · derivative · entry 1 Hogue Dale Curtis Jr. · CIK 0002006649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-12-28 F1 · derivative.exercise_date: One-thirty sixth of the shares underlying the option vest in equal monthly installments measured from December 29, 2023, with the first vesting occurring on January 29, 2024, subject to the Reporting Person's continued service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.